Total Voting Rights

Ergomed plc

01 August 2023

 

Total Voting Rights

Guildford, UK - 1 August 2023: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 31 July 2023 consisted of 50,811,805 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

ENDS

Enquiries:

Ergomed plc                                                                           Tel: [phone]

Dr Miroslav Reljanović (Executive Chairman)      

Jonathan Curtain (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets and

Strategy)

Numis  (Nominated Advisor and Joint Broker)                            Tel: [phone]

Freddie Barnfield / Euan Brown/ Jack McLaren  

Peel Hunt LLP  (Joint Broker)                                                    Tel: [phone]

James Steel / Dr Christopher Golden

Consilium Strategic Communications  - for UK enquiries         Tel: [phone]

Chris Gardner / Matthew Neal                                                     [e-mail]

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.

 

END